Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CytoDynSTU:296 -3.03%34 Net Debt Paydown Yield % is 0.53% as of Jul. 19, 2026, which is 18% above its 10-year median of 0.45. GuruFocus rates STU:296 with a GF Score™ of 34/100. The stock has 1 warning sign investors should review. Among 1,163 Biotechnology companies, CytoDyn ranks better than 68.1% on this metric.
Net Debt Paydown Yield % is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. It is a measure of a company's willingness and ability to reduce its debt.
As of today, CytoDyn's Net Debt Paydown Yield % was 0.53%.
CytoDyn (STU:296) Net Debt Paydown Yield % Explanation
Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced. In other words, it is a measure of the willingness and ability of a firm's management to pay down debt. Companies that have high debt paydown yields indicate that they are more aggressive with paying down debt.
In the calculation of Net Debt Paydown Yield %, we use the reductions of TTM average total debt one-year-ago and TTM average total debt at present, divided by its Market Cap.
The historical data trend for CytoDyn's Net Debt Paydown Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:296 vs VSTM, IRD, PALI: Net Debt Paydown Yield % Comparison
For the Biotechnology subindustry, CytoDyn's Net Debt Paydown Yield %, along with its competitors' market caps and Net Debt Paydown Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CytoDyn Net Debt Paydown Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CytoDyn's Net Debt Paydown Yield % distribution charts can be found below:
* The bar in red indicates where CytoDyn's Net Debt Paydown Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Net Debt Paydown Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.
What does a Net Debt Paydown Yield % of 0.53% mean?
CytoDyn (STU:296) has a Net Debt Paydown Yield % of 0.53% as of Jul. 19, 2026. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on CytoDyn and its competitors. This is 18% above median its historical median of 0.45. According to the industry distribution chart, CytoDyn ranks #371 out of 1163 companies in the Biotechnology industry, placing it in the top 31.9%.
Is CytoDyn's Net Debt Paydown Yield % too high?
CytoDyn's current Net Debt Paydown Yield % of 0.53% is 18% above median its 10-year median of 0.45. The Biotechnology industry median Net Debt Paydown Yield % is 0.03. CytoDyn's value of 0.53% is 1666.7% above this industry median. Based on the distribution chart, CytoDyn ranks #371 out of 1163 companies in the Biotechnology industry, which is above the industry midpoint. Overall, CytoDyn has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does CytoDyn's Net Debt Paydown Yield % compare to VSTM and IRD?
According to the Biotechnology industry distribution chart, CytoDyn ranks #371 out of 1163 companies for Net Debt Paydown Yield %. This puts CytoDyn in the upper half of its industry. The industry median Net Debt Paydown Yield % is 0.03. CytoDyn's value of 0.53% is 1666.7% above this benchmark. While the company's 10-year median is 0.45 vs. the industry median of 0.03, CytoDyn has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Debt Paydown Yield % for a Biotechnology company?
The median Net Debt Paydown Yield % among Biotechnology companies is 0.03, based on 1,163 companies in the industry. Companies in the top quartile (top 25%) have a Net Debt Paydown Yield % significantly above this median, while those in the bottom quartile fall well below. However, Net Debt Paydown Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CytoDyn's current Net Debt Paydown Yield % of 0.53% is 1666.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Debt Paydown Yield % mean?
A high Net Debt Paydown Yield % can signal that a stock is expensive relative to its fundamentals. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on CytoDyn and its competitors. For the Biotechnology industry, the median Net Debt Paydown Yield % is 0.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CytoDyn's current Net Debt Paydown Yield % is 0.53%, which is 18% above median its own 10-year median of 0.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CytoDyn stock overvalued right now?
CytoDyn (STU:296) has a current Net Debt Paydown Yield % of 0.53%. The current Net Debt Paydown Yield % is 0.53%, which is 18% above median its 10-year median of 0.45 and 1666.7% above the Biotechnology industry median of 0.03. CytoDyn's overall GF Score™ is 34/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Debt Paydown Yield % calculated?
Net Debt Paydown Yield % is calculated from a company's financial statements. For CytoDyn (STU:296), the current Net Debt Paydown Yield % is 0.53% as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CytoDyn Inc is a USA-based clinical-stage biotechnology company that focuses on the clinical development and potential commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The product candidate is PRO 140, which is a class of HIV therapy called entry inhibitors that block HIV from entering into and infecting certain cells. The company emphasizes exploring opportunities for clinical applications for PRO 140 involving the CCR5 (C-C chemokine receptor type 5) receptor, other than HIV-related treatments, such as inflammatory conditions, autoimmune diseases, and cancer.
34GF Score
Get the complete analysis for STU:296
Net Debt Paydown Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:296 has been successfully added to your 
